Clinical trials: Hepatitis E
Hepatitis B, Chronic
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB).
- Trial name
- NCT05867056
- Testing
- IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Immunocore Ltd
Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection
Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection
Hepatitis E is a worldwide disease. It is the leading or second leading cause of acute hepatitis in adults in developing countries from sub-Saharan Africa or Southeast Asia, where it is hyperendemic and principally water-borne.
- Trial name
- NCT01090232
- Testing
- blood samples
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Hepatitis B, Chronic
Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from Hansoh Pharmaceutical of China, in combination…
- Trial name
- PEG-Tα1 (NCT02366247)
- Testing
- PEG-Tα1, Adefovir
- Where
- 32 sites in China
- Volunteers
- 463 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Hepatitis B
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
- Trial name
- NCT03780543
- Testing
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 92 people
- Sponsor
- Assembly Biosciences
Hepatitis E, Hepatitis B
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
This is a open label, randomized phase VI study, to assess the safety and immunogenicity of co-administration of Hepatitis E vaccine with Hepatitis B vaccine.
- Trial name
- NCT02584543
- Testing
- HEV vaccine, HBV vaccine
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Chronic Hepatitis B
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B
Currently, seven medications are approved for the treatment of hepatitis B: two formulations of interferon and five nucleons(t)ide analogues.
- Trial name
- NCT01906580
- Testing
- Peg-IFNα-2a, Entecavir
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis B
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen negative.
- Trial name
- NCT00035789
- Testing
- Entecavir
- Where
- 31 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis E
Prevalence of Hepatitis E During Follow-up Liver and Kidney Transplant Patients in Guadeloupe, French West Indies
Hepatitis E is well known to be a common cause of severe hepatitis on organ-transplanted people. However, several studies also show a risk of transition to a chronic state.
- Trial name
- KARU-HEP (NCT07729202)
- Testing
- Liver and Kidney transplanted patients
- Where
- Guadeloupe
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Hepatitis E
Exposure to Hepatitis E Virus in Occitania, France
The objective of the proposed work is to determine the seroprevalence of HEV in 2023 in a population of blood donors living in Occitania. Compare the current frequency of anti-HEV IgG and IgM markers with that of 2011.
- Trial name
- EVE (NCT06137313)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
This study will evaluate the efficacy, safety, and tolerability of PEGASYS in participants with HBeAg-negative chronic HBV. The anticipated time on study treatment is 48 weeks, and the target sample size is 60 individuals.
- Trial name
- NCT02570191
- Testing
- Peginterferon alfa-2a
- Where
- 8 sites in Bulgaria
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B, Hepatitis B, Chronic
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as…
- Trial name
- NCT05630820
- Testing
- Bepirovirsen
- Where
- 171 sites in United States, Argentina and 25 more
- Volunteers
- 857 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04023721
- Testing
- Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors
- Where
- 7 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- F-star Therapeutics, Inc.
Hepatitis B, Chronic
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from Hansoh Pharmaceutical of China, in combination…
- Trial name
- PEG-Tα1 (NCT02366208)
- Testing
- PEG-Tα1, Adefovir
- Where
- 12 sites in China
- Volunteers
- 116 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Hepatitis B
Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy
This study evaluates whether Peg-IFN alfa-2a can reduce the recurrence rate of hepatitis B in 96 weeks after nucleoside analogue (NUC) withdrawal.
- Trial name
- NCT02594293
- Testing
- PegIFN alfa-2a
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Huashan Hospital
Hepatitis B, Chronic
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
This study will evaluate the efficacy and safety of peginterferon alfa-2a or ADV, in participants with lamivudine-resistant HBeAg-positive chronic hepatitis B.
- Trial name
- NCT02598063
- Testing
- Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a
- Where
- 12 sites in China, Hong Kong
- Volunteers
- 255 people
- Sponsor
- Hoffmann-La Roche
Hepatitis
A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.
The purpose of this study is to determine if a hepatitis E vaccine is safe and able to prevent symptomatic liver disease due to the hepatitis E virus.
- Trial name
- NCT00287469
- Testing
- Hepatitis E vaccine, recombinant (Sar 56 kDa)
- Where
- Nepal
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV, Hepatitis E
Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
Study of seroprevalence of hepatitis E among HIV positive patient in Basque country, France in 2016.
- Trial name
- VIhVhEpb (NCT02847507)
- Where
- France
- Volunteers
- 307 people
- Sponsor
- Centre Hospitalier de la côte Basque
Chronic Hepatitis B
Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B
This is a phase IV, 2-year, multi-center, single arm and open-label study, evaluating the efficacy and safety with using local manufactured adefovir dipivoxil in Chinese subjects with HBeAg negative chronic hepatitis B
- Trial name
- NCT00324961
- Testing
- adefovir dipivoxil tablets
- Where
- 18 sites in China
- Volunteers
- 533 people
- Sponsor
- GlaxoSmithKline
Hepatitis E Infection
Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.
The aim of the study is to determine the effectiveness of hepatitis E virus vaccine given in women of child bearing age in preventing HEV disease during pregnancy among women in rural Bangladesh.
- Trial name
- NCT02759991
- Testing
- Hecolin, Hepa-B
- Where
- Bangladesh
- Volunteers
- 19,460 people, healthy volunteers welcome
- Sponsor
- Norwegian Institute of Public Health
Chronic Hepatitis B
Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HT-102 (BM012) Injection in Healthy Subjects and Hepatitis B e Antigen-Negative Patients with Chronic Hepatitis B Virus Infection: A Randomized…
- Trial name
- NCT06744686
- Testing
- HT-102
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.